Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics' stock price has seen significant movement in the past six months, with a 133.53% increase over the past year. The 52-week range for the stock has been between $41.10 and $107.84. The FDA approved ICOTYDE™ for the treatment of moderate to severe plaque psoriasis. The FDA accepted the New Drug Application (NDA) for Rusfertide and granted it Priority Review as a potential first-in-class therapy for Polycythemia Vera. New one-year Phase 3 results for ICOTYDE™ in moderate-to-severe plaque psoriasis were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 28, 2026, showing sustained skin clearance and a favorable safety profile. Protagonist Therapeutics' Chief Financial Officer, Ali Asif, sold 24,765 shares of common stock for approximately $2.58 million. Protagonist reported its Q4 and full-year 2025 financial results on February 25, 2026, and PTGX shares gained 1.5%.

Protagonist Therapeutics, Inc.'s products and services are not typically subject to seasonal demand fluctuations. The demand for its products is primarily driven by the prevalence of the diseases they treat and the medical community's adoption of these treatments, rather than by seasonal patterns.

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs within the Healthcare sector and Biotechnology industry. The company's technology platform targets unmet medical needs in inflammation and immunology, hematology, and metabolic diseases. Key products and pipeline candidates include Icotyde (icotrokinra / JNJ-2113), Rusfertide (PTG-300), PN-881, PN-477 and PN-458, PN-8047, L-4R alpha antagonist, and AmylinR-based oral and subcutaneous mono- and poly-agonists.

Protagonist Therapeutics, Inc. operates in the U.S. and Australia. The company's corporate headquarters are located in Newark, California, USA, and it maintains a discovery research team in Brisbane, Queensland, Australia.

Protagonist Therapeutics actively engages in initiatives that contribute to its brand reputation by focusing on advancing education related to its therapeutic areas and conducting disease awareness campaigns to educate the public. They also participate in major medical conferences, industry forums, and patient advocacy events globally. The company's reputation has likely been positively impacted by the FDA Approval of ICOTYDE™, the FDA Priority Review for Rusfertide, and positive Phase 3 Data for ICOTYDE™. While the insider stock sale by the CFO could be viewed with scrutiny, the context of the stock's significant appreciation over the past year and the exercise of options on the same day might mitigate negative reputational impact.

Protagonist Therapeutics, Inc. has a mixed ownership structure, with institutional investors holding a significant portion of the company’s stock. Approximately 61.57% to 85.25% of the company's stock is owned by institutional investors, while insiders own about 1.30% and public companies and individual investors hold around 13.45% to 23.68%. Major institutional owners include BlackRock, Inc., Farallon Capital Management Llc, Vanguard Group Inc, Rtw Investments, Lp, State Street Corp, Wellington Management Group Llp, UBS Group AG, Janus Henderson Group Plc, Johnson & Johnson, and Invesco Ltd. The largest individual shareholder is Julie Papanek, owning 2.45 million shares, representing 3.84% of the company.